These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22705672)

  • 1. Re: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.
    Freshwater MF
    Ann Plast Surg; 2012 Jul; 69(1):111; author reply 111-2. PubMed ID: 22705672
    [No Abstract]   [Full Text] [Related]  

  • 2. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.
    Armendariz-Borunda J; Lyra-Gonzalez I; Medina-Preciado D; Gonzalez-García I; Martinez-Fong D; Miranda RA; Magaña-Castro R; Peña-Santoyo P; Garcia-Rocha S; Bautista CA; Godoy J; Flores-Montana J; Floresvillar-Mosqueda J; Armendariz-Vazquez O; Lucano-Landeros MS; Vazquez-Del Mercado M; Sanchez-Parada MG
    Ann Plast Surg; 2012 Jan; 68(1):22-8. PubMed ID: 21659848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of minocycline on hypertrophic scarring.
    Smoot EC
    Plast Reconstr Surg; 2008 Mar; 121(3):1070. PubMed ID: 18317174
    [No Abstract]   [Full Text] [Related]  

  • 4. Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.
    Levitt J; Gould MK
    Am J Respir Crit Care Med; 2005 Nov; 172(9):1228-9; author reply 1229. PubMed ID: 16249322
    [No Abstract]   [Full Text] [Related]  

  • 5. Idiopathic pulmonary fibrosis and pirfenidone.
    Collard HR
    Eur Respir J; 2010 Apr; 35(4):728-9. PubMed ID: 20356985
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypertrophic scarring: the greatest unmet challenge after burn injury.
    Finnerty CC; Jeschke MG; Branski LK; Barret JP; Dziewulski P; Herndon DN
    Lancet; 2016 Oct; 388(10052):1427-1436. PubMed ID: 27707499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The questionable efficacy of pirfenidone in IPF.
    Mathai SC; Polito AJ
    Am J Respir Crit Care Med; 2005 Nov; 172(9):1228. PubMed ID: 16249323
    [No Abstract]   [Full Text] [Related]  

  • 9. Pirfenidone: Clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis.
    Bando M
    Respir Investig; 2016 Sep; 54(5):298-304. PubMed ID: 27566376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of bilidase for the treatment of experimental hypertrophic postburn cicatrices.
    Loladze M; Alibegashvili M; Turmanidze Ts; Iashvili B; Kutivadze D; Chanishvili T
    Bull Exp Biol Med; 2005 Jan; 139(1):98-100. PubMed ID: 16142289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study in patients with established advanced liver fibrosis using pirfenidone.
    Armendáriz-Borunda J; Islas-Carbajal MC; Meza-García E; Rincón AR; Lucano S; Sandoval AS; Salazar A; Berumen J; Alvarez A; Covarrubias A; Aréchiga G; García L
    Gut; 2006 Nov; 55(11):1663-5. PubMed ID: 17047115
    [No Abstract]   [Full Text] [Related]  

  • 12. [A systematic analysis of the compression pressure in the compression therapy for scars in childhood with the help of the Kikuhime® pressure device].
    Keller K; Krenzer-Scheidemantel G; Meyer T
    Zentralbl Chir; 2014 Dec; 139(6):638-42. PubMed ID: 21480169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The early management of the burn wound and observations on hypertrophic scarring. With special reference to the deep dermal level and hypertrophic scarring.
    Hersch SJ
    S Afr J Surg; 1994 Mar; 32(1):1-4. PubMed ID: 11218432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
    Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
    Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
    [No Abstract]   [Full Text] [Related]  

  • 15. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Poletti V; Ravaglia C; Tomassetti S
    Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone for idiopathic pulmonary fibrosis.
    Bouros D
    Lancet; 2011 May; 377(9779):1727-9. PubMed ID: 21571363
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical decisions in hepatology: the pirfenidone case analysis.
    Chavez-Tapia NC; Méndez-Sánchez N
    Ann Hepatol; 2014; 13(2):163-5. PubMed ID: 24552857
    [No Abstract]   [Full Text] [Related]  

  • 18. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
    Dosanjh A
    Eur J Pharmacol; 2006 May; 536(3):219-22. PubMed ID: 16581063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of mugwort lotion for the treatment of post-burn hypertrophic scars.
    Ogawa R; Hyakusoku H; Ogawa K; Nakao C
    J Plast Reconstr Aesthet Surg; 2008; 61(2):210-2. PubMed ID: 18033748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.